VSee Health (VSEE) said Monday it expanded its telehealth service offering by launching a new specialized program that will integrate GLP-1 prescription medicines within its existing offerings and is designed to address obesity and related health risks.
The GLP-1 initiative will combine telehealth access, prescription drug support and behavioral intervention, with participants set to receive personalized care plans, virtual support calls and access to GLP-1 medicines. The program provides subscriptions at $4.99 a month, VSee said.
Shares of the company were up 26% in recent Monday premarket activity.
Price: 2.0700, Change: +0.43, Percent Change: +26.22
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.